Comparative Pharmacology
Head-to-head clinical analysis: LUMATEPERONE TOSYLATE versus RISPERDAL CONSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMATEPERONE TOSYLATE versus RISPERDAL CONSTA.
LUMATEPERONE TOSYLATE vs RISPERDAL CONSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lumateperone tosylate is an atypical antipsychotic with a unique mechanism of action involving antagonism of serotonin 5-HT2A receptors, partial agonism of serotonin 5-HT1A receptors, and antagonism of dopamine D2 receptors; it also modulates glutamate via phosphorylation of GluN2B subunits and inhibits serotonin reuptake.
Risperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also binds to alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors, with low affinity for muscarinic receptors. The combination of 5-HT2A and D2 antagonism is thought to improve negative symptoms and reduce extrapyramidal side effects.
42 mg orally once daily
25 mg intramuscular every 2 weeks; may increase to 37.5 mg or 50 mg after 4 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 24-29 hours, allowing once-daily dosing. Steady-state reached in about 5 days.
The terminal elimination half-life of risperidone is approximately 20 hours for CYP2D6 extensive metabolizers and 24 hours for poor metabolizers (accounting for both risperidone and 9-hydroxyrisperidone). The half-life of the active moiety is about 20 hours, allowing for biweekly dosing of the long-acting injection.
Approximately 60% excreted in urine as metabolites (unchanged drug negligible) and 30% in feces via biliary elimination.
Risperidone and its active metabolite 9-hydroxyrisperidone are primarily excreted renally (70%), with 14% excreted in feces. The remainder is eliminated via biliary and metabolic pathways.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic